Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Return on Capital Employed (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Return on Capital Employed for 15 consecutive years, with 0.01% as the latest value for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 17.0% year-over-year to 0.01%; the TTM value through Mar 2026 reached 0.01%, down 17.0%, while the annual FY2025 figure was 0.07%, 17.0% down from the prior year.
  • Return on Capital Employed hit 0.01% in Q1 2026 for Corcept Therapeutics, down from 0.07% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.34% in Q1 2022 and bottomed at 0.01% in Q1 2026.
  • Average Return on Capital Employed over 5 years is 0.2%, with a median of 0.21% recorded in 2023.
  • Year-over-year, Return on Capital Employed rose 13bps in 2022 and then dropped -17bps in 2026.
  • Corcept Therapeutics' Return on Capital Employed stood at 0.23% in 2022, then fell by -8bps to 0.21% in 2023, then fell by -4bps to 0.2% in 2024, then plummeted by -67bps to 0.07% in 2025, then plummeted by -118bps to 0.01% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.01%, 0.07%, and 0.1% for Q1 2026, Q4 2025, and Q3 2025 respectively.